Novartis Says Beovu Matched Rival Eylea In Visual Acuity In Eye Disease

Novartis on Monday said its eye drug Beovu matched rival Eylea from Regeneron in visual acuity at one year in patients with diabetic macular edema (DME), as the Swiss drugmaker seeks to regain momentum with the drug after early safety stumbles.

from Top Business News- News18.com https://ift.tt/2FwL6Qf

• Tweet
• Share
• Share
• Share
• Share